MedTrace Logo

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

NCT02383927 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2024-07-11

Study results available
· View outcomes & findings →

Summary

Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.

Conditions

  • Thyroid Cancer
  • Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
  • HRAS Mutant Tumor
  • Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor

Interventions

DRUG

Tipifarnib

FTase inhibitor

Sponsors & Collaborators

  • Kura Oncology, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-13
Primary Completion
2020-12-14
Completion
2020-12-14

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02383927 on ClinicalTrials.gov